vs
Side-by-side financial comparison of Crinetics Pharmaceuticals, Inc. (CRNX) and Rithm Property Trust Inc. (RPT). Click either name above to swap in a different company.
Crinetics Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($6.2M vs $3.4M, roughly 1.8× Rithm Property Trust Inc.). Rithm Property Trust Inc. runs the higher net margin — 95.4% vs -1993.4%, a 2088.8% gap on every dollar of revenue.
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
Rithm Capital Corp. (Rithm) is an American investment management company headquartered in New York that focuses on real estate and alternative investments.
CRNX vs RPT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.2M | $3.4M |
| Net Profit | $-122.8M | $3.2M |
| Gross Margin | — | — |
| Operating Margin | -2169.6% | 99.6% |
| Net Margin | -1993.4% | 95.4% |
| Revenue YoY | — | -39.7% |
| Net Profit YoY | -52.4% | 11.2% |
| EPS (diluted) | $-1.30 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.2M | $3.4M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | $1.0M | $4.2M | ||
| Q1 25 | — | $249.0K | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q4 23 | $0 | — | ||
| Q3 23 | — | $1.1M |
| Q4 25 | $-122.8M | $3.2M | ||
| Q3 25 | — | $-273.0K | ||
| Q2 25 | $-115.6M | $1.9M | ||
| Q1 25 | — | $-3.4M | ||
| Q4 24 | $-80.6M | — | ||
| Q3 24 | $-76.8M | — | ||
| Q4 23 | $-60.1M | — | ||
| Q3 23 | — | $-5.5M |
| Q4 25 | -2169.6% | 99.6% | ||
| Q3 25 | — | -6.2% | ||
| Q2 25 | -12523.0% | 45.7% | ||
| Q1 25 | — | -1416.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -533.4% |
| Q4 25 | -1993.4% | 95.4% | ||
| Q3 25 | — | -6.8% | ||
| Q2 25 | -11216.0% | 45.1% | ||
| Q1 25 | — | -1363.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -526.3% |
| Q4 25 | $-1.30 | $-0.26 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | $-1.23 | $0.01 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | $-0.86 | — | ||
| Q3 24 | $-0.96 | — | ||
| Q4 23 | $-0.89 | — | ||
| Q3 23 | — | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.0B | $79.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $992.1M | $291.6M |
| Total Assets | $1.1B | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.0B | $79.3M | ||
| Q3 25 | — | $81.4M | ||
| Q2 25 | $1.2B | $98.6M | ||
| Q1 25 | — | $97.4M | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $862.7M | — | ||
| Q4 23 | $558.6M | — | ||
| Q3 23 | — | $63.9M |
| Q4 25 | $992.1M | $291.6M | ||
| Q3 25 | — | $291.7M | ||
| Q2 25 | $1.2B | $294.7M | ||
| Q1 25 | — | $296.1M | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $833.0M | — | ||
| Q4 23 | $539.1M | — | ||
| Q3 23 | — | $320.2M |
| Q4 25 | $1.1B | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | $1.3B | $1.0B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $937.4M | — | ||
| Q4 23 | $635.4M | — | ||
| Q3 23 | — | $1.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-92.9M | $-8.3M |
| Free Cash FlowOCF − Capex | $-93.4M | — |
| FCF MarginFCF / Revenue | -1515.3% | — |
| Capex IntensityCapex / Revenue | 7.4% | — |
| Cash ConversionOCF / Net Profit | — | -2.56× |
| TTM Free Cash FlowTrailing 4 quarters | $-311.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-92.9M | $-8.3M | ||
| Q3 25 | — | $-5.8M | ||
| Q2 25 | $-85.9M | $-25.0K | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | $-64.7M | — | ||
| Q3 24 | $-62.8M | — | ||
| Q4 23 | $-40.8M | — | ||
| Q3 23 | — | $-10.7M |
| Q4 25 | $-93.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-89.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-65.7M | — | ||
| Q3 24 | $-63.4M | — | ||
| Q4 23 | $-41.7M | — | ||
| Q3 23 | — | — |
| Q4 25 | -1515.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -8637.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | 7.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 310.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 0.0% |
| Q4 25 | — | -2.56× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRNX
| Products | $5.4M | 88% |
| Other | $741.0K | 12% |
RPT
Segment breakdown not available.
